The HER2 amplification for colorectal cancer enhanced stratification (HERACLES) trial was a multicenter, open-label Phase II clinical trial in patients with CRC resistant to chemotherapy and anti-EGFR therapy. This evidence concerns the gene ERBB2 and colorectal cancer.